Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis

[1]  F. Barkhof,et al.  Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. , 2012, Archives of neurology.

[2]  K. Khan,et al.  Microvascular changes associated with passive immunotherapy in PDAPP mice: Potential implication for the etiology of vasogenic edema , 2011, Alzheimer's & Dementia.

[3]  J. Suhy,et al.  Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer’s disease study cohorts from phase 3 trials of semagacestat and solanezumab , 2011, Alzheimer's & Dementia.

[4]  Clifford R. Jack,et al.  Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup , 2011, Alzheimer's & Dementia.

[5]  A. Hofman,et al.  Incidence of Cerebral Microbleeds in the General Population: The Rotterdam Scan Study , 2011, Stroke.

[6]  M. Sabbagh,et al.  Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient. , 2011, Journal of Alzheimer's disease : JAD.

[7]  C. Holmes,et al.  Neuropathology after active Aβ42 immunotherapy: implications for Alzheimer’s disease pathogenesis , 2010, Acta Neuropathologica.

[8]  F Barkhof,et al.  Incidence of cerebral microbleeds , 2010, Neurology.

[9]  Brad J Kolls,et al.  A PHASE 2 MULTIPLE ASCENDING DOSE TRIAL OF BAPINEUZUMAB IN MILD TO MODERATE ALZHEIMER DISEASE , 2010, Neurology.

[10]  Richard J. Caselli,et al.  Amyloid load in nondemented brains correlates with APOE e4 , 2010, Neuroscience Letters.

[11]  R. Sperling,et al.  A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease , 2010, Alzheimer disease and associated disorders.

[12]  Nick C Fox,et al.  11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study , 2010, The Lancet Neurology.

[13]  W. M. van der Flier,et al.  Patients With Alzheimer Disease With Multiple Microbleeds: Relation With Cerebrospinal Fluid Biomarkers and Cognition , 2009, Stroke.

[14]  R O Weller,et al.  Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. , 2008, Brain : a journal of neurology.

[15]  D. Schmechel,et al.  Human apolipoprotein E4 targeted replacement mice show increased prevalence of intracerebral hemorrhage associated with vascular amyloid deposition. , 2008, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[16]  R. Barbour,et al.  Immunotherapy Reduces Vascular Amyloid-β in PDAPP Mice , 2008, The Journal of Neuroscience.

[17]  R. Carare,et al.  Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. , 2008, Brain pathology.

[18]  T. Grabowski.  Course of cerebral amyloid angiopathy–related inflammation , 2008 .

[19]  R. Carare,et al.  SYMPOSIUM: Clearance of Aβ from the Brain in Alzheimer's Disease: Perivascular Drainage of Amyloid‐β Peptides from the Brain and Its Failure in Cerebral Amyloid Angiopathy and Alzheimer's Disease , 2007 .

[20]  Aad van der Lugt,et al.  O3-04-07 Prevalence and risk factors of cerebral microbleeds in the Rotterdam scan study , 2006, Alzheimer's & Dementia.

[21]  D. Holtzman,et al.  Human Apolipoprotein E4 Alters the Amyloid-β 40:42 Ratio and Promotes the Formation of Cerebral Amyloid Angiopathy in an Amyloid Precursor Protein Transgenic Model , 2005, The Journal of Neuroscience.

[22]  J. Krakauer,et al.  Reversible leukoencephalopathy associated with cerebral amyloid angiopathy , 2004, Neurology.

[23]  M. Frosch,et al.  Clinical manifestations of cerebral amyloid angiopathy–related inflammation , 2004, Annals of neurology.

[24]  S. Love,et al.  APOEɛ4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of Aβ protein , 2003 .

[25]  S. Love,et al.  APOE epsilon 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A beta protein. , 2003, Neuropathology and applied neurobiology.

[26]  P. Scheltens,et al.  A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT , 2001, Stroke.

[27]  M. Moskowitz,et al.  Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy. , 2001, The American journal of pathology.

[28]  B. Hyman,et al.  Apolipoprotein E ϵ4 and cerebral hemorrhage associated with amyloid angiopathy , 1995 .

[29]  B. Hyman,et al.  Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. , 1995, Annals of neurology.

[30]  F. Fazekas,et al.  Pathologic correlates of incidental MRI white matter signal hyperintensities , 1993, Neurology.